Income statement, balance sheet and cash flow statement for the last 6 fiscal years, taken from the XBRL data OKYO Pharma Ltd files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2020
FY2022
FY2022
FY2023
FY2024
FY2025
Research and development
0.52
0.35
1.61
6.34
8.24
2.25
Interest expense
0
0
0.1
1.05
0.88
Interest income
0.05
0.01
Pre-tax income
-1.62
-3.38
-6.22
-13.3
-16.8
-7.97
Income tax
0.08
0.02
0.79
0.01
-0.02
3.26
Net income
-1.54
-3.35
-5.43
-13.3
-16.8
-4.71
EPS, basic
-0.32
-0.36
-0.61
-0.57
-0.20
EPS, diluted
-0.32
-0.36
-0.61
-0.57
-0.20
Balance sheet
FY2020
FY2022
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
0.24
6.89
2.7
4.05
0.83
1.56
Receivables
0.04
0.81
0.59
Total current assets
6.99
4.3
5.2
1.54
3.68
Property, plant and equipment
0.01
0.01
0.01
0
0
Lease right-of-use assets
0.03
0.1
Total assets
7.09
4.3
5.2
1.54
3.68
Accounts payable
1.67
1.31
4.26
7.06
8.37
Short-term debt
2.7
Total current liabilities
1.71
1.35
7.26
7.42
9.23
Lease liabilities
0.06
Total liabilities
1.77
1.35
7.26
7.42
9.23
Paid-in capital
112
124
131
143
147
Retained earnings
-106
-112
-126
-143
-143
Total equity
-0.14
5.32
2.95
-2.05
-5.88
-5.55
Total liabilities and equity
7.09
4.3
5.2
1.54
3.68
Cash flow statement
FY2020
FY2022
FY2022
FY2023
FY2024
FY2025
Net income
-1.54
-3.35
-5.43
-13.3
-16.8
-4.71
Depreciation and amortization
0
0
0
0
0
0
Cash from operations
-1.2
-1.6
-5.47
-7.7
-9.49
-1.81
Capital expenditures
-0.01
-0
-0.01
-0
Cash from investing
-0.13
-0.02
-0
-0.01
-0
Stock issued
0.99
0.23
7.32
Cash from financing
0.96
7.83
2.15
9.32
6.21
2.66
Exchange rate effect
-0.02
0.45
-0.87
-0.28
0.06
-0.11
Net change in cash
-0.37
6.21
-3.32
1.62
-3.28
0.84
Free cash flow
-1.61
-5.47
-7.7
-1.81
Key metrics
Worked out from the statements above. Latest values use fiscal 2025. Valuation uses the share price of $1.38 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on assets (ROA)
-180.4%
Net income / average total assets.
Growth
Metric
Value
How it is calculated
Total assets growth, 1y
138.6%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-5.1%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
0.40x
Current assets / current liabilities.
Quick ratio
0.17x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.17x
(Cash + short-term investments) / current liabilities.
Liabilities / assets
250.9%
Total liabilities / total assets.
Working capital
-$5.6M
Current assets - current liabilities.
Per share
Metric
Value
How it is calculated
EPS, diluted
-$0.20
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
EPS, basic
-$0.20
Net income per basic share, as reported (split-adjusted).
Valuation
Metric
Value
How it is calculated
Market cap
$46.7M
Share price x shares outstanding.
Enterprise value
$45.1M
Market cap + total debt - cash - short-term investments.
FCF yield
-3.9%
Free cash flow / market cap.
Earnings yield
-10.1%
Net income / market cap (the inverse of P/E).
Was OKYO Pharma Ltd profitable in fiscal 2025?
No. It reported a net loss of $4.7M.
How much free cash flow did OKYO Pharma Ltd generate in fiscal 2025?
Cash from operations of $1.8M minus capital expenditures of $1.2K left free cash flow of -$1.8M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.